APM
KYMR icon

Avidity Partners Management’s Kymera Therapeutics KYMR Stock Holding History

Avidity Partners Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500,000
Closed -$20.1M – 79
2024
Q4 		$20.1M Hold
500,000
– – 1.98% 19
2024
Q3 		$23.7M Buy
+500,000
New +$22.1M 1.21% 34
2022
Q1 		– Sell
-670,000
Closed -$42.5M – 100
2021
Q4 		$42.5M Buy
670,000
+155,500
+30% +$9.06M 0.9% 37
2021
Q3 		$30.2M Buy
+514,500
New +$29.8M 0.67% 49

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Avidity Partners Management's KYMR Position: Q1 2025 in Review

Avidity Partners Management sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 500,000 shares — an estimated $20.1M sold.

Avidity Partners Management first reported a position in KYMR in Q3 2021 and held it in 4 quarters. The position peaked at $42.5M in Q4 2021. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • Avidity Partners Management reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avidity Partners Management sold 500,000 Kymera Therapeutics shares in Q1 2025, an estimated $20.1M.
  • Avidity Partners Management first reported a position in Kymera Therapeutics in Q3 2021 and held it in 4 quarters.
  • Avidity Partners Management's Kymera Therapeutics position peaked at $42.5M in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.